Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tradipitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.35 |
| ▸ | RORB | Q92753 | 10/20 | 0.42 |
| ▸ | RORC | P51449 | 5/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tradipitant SCHEMBL29810017 | 1.00 | RORB (0.42) | RORBRORCIDH1KDRMAPK1 | |
| SCHEMBL4708282 | 0.95 | RORB (0.40) | RORBRORCIDH1KDRMAPK1 | |
| SCHEMBL4707172 | 0.95 | RORB (0.46) | RORBRORCGRM2 | |
| SCHEMBL25479760 | 0.94 | RORB (0.39) | RORBRORCIDH1MAPK1GRM2 | |
| SCHEMBL4707594 | 0.93 | RORB (0.43) | RORBRORCGRM2 | |
| SCHEMBL4705482 | 0.92 | RORB (0.41) | RORBRORCIDH1GRM2TRPV1 | |
| SCHEMBL4706229 | 0.92 | IDH1 (0.44) | RORBRORCIDH1KDRGRM2 | |
| SCHEMBL4707077 | 0.91 | RORB (0.39) | RORBRORCIDH1MAPK1GRM2 | |
| SCHEMBL4708209 | 0.91 | RORB (0.39) | RORBRORCIDH1MAPK1GRM2 | |
| SCHEMBL4706212 | 0.90 | KDR (0.37) | KDRTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3730140-B1 | TRADIPITANT FOR USE IN TREATING NAUSEA OR VOMITING | VANDA PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12582640-B2 | Treatment of lower respiratory tract infection with tradipitant | VANDA PHARMACEUTICALS INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260008856-A1 | METHODS OF TREATING DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BLUEFIN BIOMEDICINE INC (US) | 2026-01-08 | — | — | US | claimed |
| EP-4637766-A1 | METHODS OF TREATMENT WITH TRADIPITANT | Vanda Pharmaceuticals Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4110335-B1 | IMPROVED TREATMENT OF ATOPIC DERMATITIS WITH TRADIPITANT | VANDA PHARMACEUTICALS INC (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250255855-A1 | METHOD OF TREATMENT WITH TRADIPITANT | VANDA PHARMACEUTICALS INC. | 2025-08-14 | — | — | US | claimed |
| EP-4599831-A1 | TREATMENT OF GASTROPARESIS WITH TRADIPITANT | Vanda Pharmaceuticals Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250205213-A1 | METHOD OF TREATMENT WITH TRADIPITANT | VANDA PHARMACEUTICALS INC. | 2025-06-26 | — | — | US | claimed |
| US-7381826-B2 | Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | claimed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | claimed |
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | claimed |
| JP-2007509143-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20070078166-A1 | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3] triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-04-05 | — | — | US | claimed |
| EP-1675846-A1 | NOVEL CRYSTALLINE FORMS OF {2-[1-(3,5-BIS-TRIFLUOROMETHYLBENZYL)-5-PYRIDIN-4-YL-1H- [1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-CHLOROPHENYL)-METHANONE | ELI LILLY AND COMPANY (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | claimed |
| WO-2005042515-A1 | NOVEL CRYSTALLINE FORMS OF {2-[1-(3,5-BIS-TRIFLUOROMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-CHLOROPHENYL)-METHANONE | ELI LILLY AND COMPANY (US) | 2005-05-12 | — | — | WO | claimed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003091226-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | TACR1 1/4885RORB 2614/4885RORC 2723/4885 |
| US-20250205213-A1 | METHOD OF TREATMENT WITH TRADIPITANT | TPMT, ENTPD5, GBA1 | TACR1 2636/4885RORB 2463/4885RORC 2594/4885 |
| US-20260008856-A1 | METHODS OF TREATING DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES | IL23R, CCR1, IL1RN | TACR1 200/4885RORB 1417/4885RORC 305/4885 |
| US-20250255855-A1 | METHOD OF TREATMENT WITH TRADIPITANT | FABP6, SLC10A2, SLC27A1 | TACR1 1988/4885RORB 4752/4885RORC 4792/4885 |
| US-20070078166-A1 | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3] triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | PLK2, PDXK, PLK3 | TACR1 4779/4885RORB 2754/4885RORC 2384/4885 |
| US-12582640-B2 | Treatment of lower respiratory tract infection with tradipitant | TMPRSS2, HAVCR2, IFNAR1 | TACR1 67/4885RORB 1889/4885RORC 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.